PL EN
REVIEW PAPER
Fibromyalgia
,
 
,
 
 
 
More details
Hide details
1
Oddział II Centrum Rehabilitacji w Konstancinie
 
2
Oddział II Centrum Rehabilitacji w Konstancinie; Klinika Rehabilitacji Warszawskiego Uniwersytetu Medycznego
 
 
Med Og. 2010;16(3):303-314
 
KEYWORDS
ABSTRACT
Fibromyalgia (FM) is a clinical syndrome characterized by generalized pain in the musculoskeletal system, chronic fatigue, sleep disturbances and cognitive dysfunctions. FM is considered a central nervous system disorder resulting in improper processing of impulses and qualitative alternations of pain sensation due to central sensitization and disorder of the endogenic antinociceptive mechanism. Theories on FM etiopathogenesis include interactions of disorders of neurotransmitters’ metabolism and abnormalities in autonomic, endocrine and immune systems, constitutional, genetic and environmental factors. Symptoms and signs of FM significantly decrease the quality of life and exert an unfavourable effect on patients’ functioning in home and environmental settings. Classification of FM was emphasized in the context of different reactivity of particular groups of patients towards different treatment strategies. A comprehensive approach based on non-pharmacological interventions (aerobic exercises, behavioural-cognitive therapy and patient education) with pharmacological support (agents enhancing efferent antinociceptive tracts and decreasing neuronal activity) show the highest therapeutic effectiveness.
REFERENCES (15)
1.
Abeles A.M., Pillinger M.H., Solitar B.M. i wsp.: Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med 2007; 146(10):726-34.
 
2.
Arnold L.M., Hudson J.I., Hess E.V. i wsp.: Family study of fibromyalgia. Arthritis Rheum 2004; 50(3):944-952.
 
3.
Carville S.F., Arendt-Nielsen S., Bliddal H. i wsp.: EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008; 67: 536-541.
 
4.
Emad Y., Ragab Y., Zeinhom F. i wsp.: Hippocampus dysfunction may explain symptoms of fibromyalgia syndrome. A study with single-voxel magnetic resonance spectroscopy. J Rheumatol 2008; 35 (7): 1371–7.
 
5.
Gracely R.H., Williams D.A.: Biology and therapy of fibromyalgia. Functional magnetc resonance imaging findings in fibromyalgia. Arthritis Res Ther 2006;8:224.
 
6.
Jensen K.B., Kosek E., Petzke F. i wsp.: Evidence of dysfunctional pain inhibition in Fibromyalgia reflected in rACC during provoked pain. Pain 2009;144(1-2):95-100
 
7.
Mc Beth J., Silman A.J., Gupta A. i wsp.: Moderation of psychosocial risk factors through dysfunction of the hypothalamic-pituitary-adrenal stress axis in the onset of chronic widespread musculoskeletal pain: findings of a population-based prospective cohort study. Arthritis Rheum 2007; 56 (1): 360–71.
 
8.
Müller W., Schneider E.M., Stratz T.: The classification of fibromyalgia syndrome. Rheumatol Int.2007; 27 (11): 1005–10.
 
9.
Pae C.U., Luyten P., Marks D.M. i wsp.: The relationship between fibromyalgia and major depressive disorder: a comprehensive review. Curr Med Res Opin 2008; 24 (8): 2359–71.
 
10.
Peterson EL.: Fibromyalgia--management of a misunderstood disorder. J Am Acad Nurse Pract 2007; 19(7):341-348.
 
11.
Petrou M., Harris R.E., Foerster B.R. i wsp.: Proton MR spectroscopy in evaluation of cerebral metabolizm in patiets with fibromyalgia: comparision with healthy controls and correlation with symptom severity. AJNR 2008;29:913-8.
 
12.
Verbunt J.A., Pernot D.H., Smeets R.J.: Disability and quality of life in patients with fibromyalgia. Health Qual Life Outcomes 2008 , 6:8.
 
13.
Wolfe F., Clauw D.J., Fitzcharles M.A. i wsp.: The American Collegeof Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. Arthit Care Res 2010; 62 (5): 600.
 
14.
Wolfe F.: Fibromyalgia wars. J Rheumatol 2009; 36 (4): 671-8.
 
15.
Wolfe F.: Fibromyalgia: the clinical syndrome. Arthritis Rheum 1989;15 (1): 1–18.
 
eISSN:2084-4905
ISSN:2083-4543
Journals System - logo
Scroll to top